amunix logo (high res no tag).png
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:00 ET | Amunix Pharmaceuticals, Inc.
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment...
amunix logo (high res no tag).png
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
June 23, 2021 07:00 ET | Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN...
amunix logo (high res no tag).png
Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety
April 12, 2021 08:00 ET | Amunix Pharmaceuticals, Inc.
AMX-818 is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated T cell engager) platform designed to improve the toxicity profile of T cell engagers for the treatment of HER2-expressing...
amunix logo (high res no tag).png
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
December 09, 2020 09:00 ET | Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT (XTENylated Protease-Activated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating...
amunix logo (high res no tag).png
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
September 17, 2020 07:00 ET | Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors –       –     Masked prodrug...
amunix logo (high res no tag).png
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
June 22, 2020 09:00 ET | Amunix Pharmaceuticals, Inc.
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
amunix logo (high res no tag).png
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
May 27, 2020 07:00 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
amunix logo (high res no tag).png
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
March 04, 2020 07:00 ET | Amunix Pharmaceuticals, Inc.
-- Harnessing clinically validated prodrug technology to advance novel pipeline of T cell engager and cytokine agents that are selectively activated in the tumor microenvironment --  -- Proprietary T...
amunix logo.jpg
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
amunix logo.jpg
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...